2025-04-11 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**0. Key Figures at a Glance:**

* **Cumulative Return (JNJ):** 23.73%
* **Cumulative Return (VOO):** 62.13%
* **Return Difference (JNJ vs VOO):** -38.4%
* **Relative Underperformance:** 40.5% (This indicates JNJ's underperformance relative to VOO is in the 40.5th percentile of historical underperformance ranges).
* **Current Price:** $148.98

**1. Company Overview and Performance Comparison:**

Johnson & Johnson is a multinational medical devices, pharmaceutical, and consumer packaged goods company.  The provided data shows that JNJ significantly underperformed the S&P 500 (VOO) over the period analyzed, with a cumulative return 38.4 percentage points lower than VOO's.  The relative underperformance indicates that this lag is near the middle of historical underperformance ranges.


**Alpha and Beta Analysis:**

The table reveals inconsistent performance relative to the market (Beta near 0 to 0.7), with periods of strong outperformance and significant underperformance.  The alpha values suggest periods of both outperformance and underperformance relative to the market's risk-adjusted return. The market capitalization remained relatively stable around $300B.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 28.0% | 56.0% | -1.0% | 0.0 | 275.1 |
| 2016-2018  | 10.0% | 10.8% | -7.0% | 0.0 | 261.0 |
| 2017-2019  | 20.0% | 10.8% | -9.0% | 0.7 | 303.3 |
| 2018-2020  | 14.0% | 59.8% | -12.0% | 0.5 | 336.1 |
| 2019-2021  | 28.0% | 59.9% | -26.0% | 0.3 | 374.6 |
| 2020-2022  | 4.0% | 61.2% | -2.0% | 0.3 | 397.0 |
| 2021-2023  | -19.0% | 61.2% | -35.0% | 0.4 | 362.9 |
| 2022-2024  | -31.0% | 61.2% | -47.0% | 0.3 | 345.4 |
| 2023-2025  | -3.0% | 69.6% | -12.0% | 0.2 | 358.7 |


**2. Recent Price Movement:**

* **Closing Price:** $148.98
* **Last Market Price:** $148.87 (down $1.39 from previous close)
* **5-Day Moving Average:** $152.53
* **20-Day Moving Average:** $159.63
* **60-Day Moving Average:** $157.08

The price is below all three moving averages, suggesting a bearish trend. The recent price drop of $1.39 reflects a short-term negative movement.


**3. Technical Indicators:**

* **Market Risk Indicator (MRI):** 0.4271 (Medium Risk)
* **RSI:** 31.55 (Suggests oversold conditions, but should be considered alongside other indicators)
* **PPO:** -1.09 (Negative PPO indicates bearish momentum)
* **Relative Strength Change (20-day):** +11.5% (Short-term upward momentum, but this is contradicted by the moving average indicators)
* **Expected Return (vs. S&P 500, long-term):** -40.9%  This suggests significant underperformance relative to the S&P 500 over a longer time horizon (2+ years) at the current price.


**4. Recent Earnings Analysis:**

| Date       | EPS   | Revenue        |
|------------|-------|----------------|
| 2024-10-23 | $1.12 | $22.47 B       |
| 2024-07-25 | $1.95 | $22.45 B       |
| 2024-05-01 | $1.35 | $21.38 B       |
| 2024-02-16 | $1.68 | $21.39 B       |
| 2023-10-27 | $10.32 | $21.35 B       |

EPS shows significant volatility, with a large spike in October 2023.  Revenue remains relatively stable.  Further investigation into the reasons for the EPS fluctuation is needed.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue   | Profit Margin |
|---------|-----------|---------------|
| 2024-12-31 | $22.52B  | 68.35%        |
| 2024-09-30 | $22.47B  | 69.01%        |
| 2024-06-30 | $22.45B  | 69.40%        |
| 2024-03-31 | $21.38B  | 69.55%        |
| 2023-12-31 | $21.39B  | 68.23%        |

Revenue is relatively consistent. Profit margins are high and generally stable, indicating strong profitability.

**Capital and Profitability:**

| Quarter | Equity     | ROE    |
|---------|------------|--------|
| 2024-12-31 | $71.49B   | 4.80%  |
| 2024-09-30 | $70.16B   | 3.84%  |
| 2024-06-30 | $71.54B   | 6.55%  |
| 2024-03-31 | $70.02B   | 4.65%  |
| 2023-12-31 | $68.77B   | 5.89%  |

Equity fluctuates slightly. ROE is generally healthy but shows some variability.


**6. Overall Analysis:**

JNJ has shown significant underperformance compared to the S&P 500 over the analyzed period. While the company demonstrates strong profitability and stable revenue, recent price action and technical indicators suggest a bearish trend.  The large discrepancy in EPS between Q4 2023 and subsequent quarters requires further investigation.  The negative long-term expected return relative to the S&P 500 raises concerns about future performance.  Further due diligence is recommended before making any investment decisions.  Considering the inherent risks involved in investing, and the analysis performed above suggests a cautious approach may be warranted.  Additional fundamental analysis and examination of industry trends is crucial for a comprehensive assessment.
